{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:16Z","timestamp":1761178576416,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.canrad.2022.06.029","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T22:53:06Z","timestamp":1661208786000},"page":"871-874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prise en charge des cancers du canal anal\u00a0: mise au point et perspectives futures"],"prefix":"10.1016","volume":"26","author":[{"given":"A.C.","family":"Delhiat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Combet-Curt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2022.06.029_bib0110","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"SFRO, SNFCP). Dig Liver Dis"},{"key":"10.1016\/j.canrad.2022.06.029_bib0115","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2022.06.029_bib0120","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0125","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0130","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11\u00a0phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0135","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72\u00a0factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0140","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03\u00a0trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA--a multicenter phase II study of chemoradiation using a 5\u00a0day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Glynne-Jones","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2022.06.029_bib0150","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.canrad.2021.11.015","article-title":"Radiotherapy of anal canal cancer","volume":"26","author":"Peiffert","year":"2022","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"10.1016\/j.canrad.2022.06.029_bib0155","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(17)30456-4","article-title":"Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study","volume":"18","author":"Sekhar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0160","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.radonc.2021.12.050","article-title":"Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)","volume":"167","author":"Martin","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0165","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1245\/s10434-015-4391-9","article-title":"The Role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis","volume":"22","author":"Jones","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2\u00a0evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-c for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0175","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of radiation therapy oncology group trials 87-04\u00a0and 98-11","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0180","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16\u00a0phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.radonc.2019.05.018","article-title":"Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904)","volume":"140","author":"Vendrely","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0190","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.514","article-title":"et al., 403MO Atezolizumab in combination with bevacizumab for patients with unresectable\/metastatic anal cancer","volume":"31","author":"Morris","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0195","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1\u00a0antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0200","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2\u00a0study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0205","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II. Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.029_bib0105","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975356","article-title":"Pooled analysis of 115\u00a0patients from updated data of Epitopes-HPV01\u00a0and Epitopes-HPV02\u00a0studies in first-line advanced anal squamous cell carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321822001330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321822001330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:35:02Z","timestamp":1761136502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321822001330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":21,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1278321822001330"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2022.06.029","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge des cancers du canal anal\u00a0: mise au point et perspectives futures","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2022.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}